InnoSkel is a pioneering platform biotechnology company developing therapies for rare skeletal diseases. InnoSkel is developing treatment options for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. InnoSkel’s lead gene therapy asset for SEDc has demonstrated compelling efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients living with skeletal dysplasia and to answer their unmet needs, keeping their voices at the heart of all we do. InnoSkel is a spin-out of the Institut de Biologie Valrose at Inserm, the French National Institute of Health and Medical Research, and is based in Nice, France.